Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Article metrics

Correction to: Leukemia (2016) 30, 1701–1707; doi:10.1038/leu.2016.148

Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.

The authors wish to apologize for any inconvenience caused.

Additional information

The online version of the original article can be found at 10.1038/leu.2016.148

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading